NASDAQ · COLL
Collegium Pharmaceutical, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for COLL: Nov 05, 2026
Collegium Pharmaceutical, Inc. Common Stock is expected to report earnings on 11/05/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $1.53. The reported EPS for the same quarter last year was $2.06.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $1.53 | $1.62 | $1.45 | 3 |
| Dec 2026 | $1.69 | $1.80 | $1.59 | 3 |
| Mar 2027 | $1.07 | $1.32 | $0.82 | 2 |
| Jun 2027 | $1.22 | $1.43 | $1.01 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · Fintel · The Motley Fool · MarketBeat- Zacks · Oct 29, 9:00 AM EDTEarnings Preview: Collegium Pharmaceutical (COLL) Q3 Earnings Expected to DeclineCollegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 27, 11:16 AM EDTHCA Healthcare Q3 Earnings Beat Estimates on Higher AdmissionsHCA's Q3 earnings and revenues beat estimates on higher admissions and ER visits, while rising costs and fewer surgeries temper growth.
- Zacks · Oct 19, 10:40 AM EDTCOLL vs. DSNKY: Which Stock Is the Better Value Option?COLL vs. DSNKY: Which Stock Is the Better Value Option?
- Zacks · Oct 16, 8:55 AM EDTDoes Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect?The consensus price target hints at an 111.4% upside potential for Collegium Pharmaceutical (COLL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- Zacks · Oct 7, 2:23 AM EDTNew Strong Sell Stocks for October 7thARDX, LUV and COLL have been added to the Zacks Rank #5 (Strong Sell) List on October 7th, 2026.
- Fintel · Sep 23, 7:09 AM EDTOppenheimer Initiates Coverage of Collegium Pharmaceutical with OutperformFintel reports that on September 23, 2026, Oppenheimer initiated coverage of Collegium Pharmaceutical (NASDAQGS:COLL) (DB:354) with a Outperform recommendation.Prior to this rating action, the stock closed at $22.78 on September 22, 2026. Collegium Pharmaceutical's stock price ha
- Fintel · Sep 9, 8:43 PM EDTLeerink Partners Initiates Coverage of Collegium Pharmaceutical with OutperformFintel reports that on September 9, 2026, Leerink Partners initiated coverage of Collegium Pharmaceutical (NASDAQGS:COLL) with a Outperform recommendation.Prior to the rating action, the company's stock closed at $23.37 on September 8, 2026, which is also the latest close as of t
- The Motley Fool · Aug 13, 8:29 AM EDTCollegium Pharmaceutical (COLL) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · Aug 6, 10:00 AM EDTCollegium Pharmaceutical (COLL) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesAlthough the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- Zacks · Aug 6, 9:50 AM EDTCollegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue EstimatesCollegium Pharmaceutical (COLL) delivered earnings and revenue surprises of +14.29% and +1.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- MarketBeat · Aug 6, 9:04 AM EDTCollegium Pharmaceutical Q2 Earnings Call Highlights5 Hot Stocks With Summer Buybacks You Can Cash In OnCollegium Pharmaceutical (NASDAQ:COLL) reported second-quarter 2026 net product revenue of $199.9 million, up 6% from a year earlier, as growth in its ADHD franchise and BELBUCA helped offset lower revenue from the NUCYNTA pain
- Zacks · Aug 3, 5:45 PM EDTCrinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Tops Revenue EstimatesCRINETICS PHARM (CRNX) delivered earnings and revenue surprises of +7.32% and +69.28%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Collegium Pharmaceutical, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.